Activation of Various Downstream Signaling Molecules by IGFBP-3

Hanief Mohammad Shahjee, Nisan Bhattacharyya

Diabetes Branch, NIDDK, National Institutes of Health, Bethesda, USA.

DOI: 10.4236/jct.2014.59091                

Abstract

Insulin-like growth factor binding protein-3 (IGFBP-3), a secretory protein, is the most abundant IGF binding protein present in human serum among all IGF binding proteins. IGFBP-3 shows decreased level of expression in cancerous cells but has been known to be present in significant amounts in normal or non-cancerous cells. IGFBP-3 can induce apoptosis in prostate cancer cells either in an IGF-dependent manner or independently of IGF binding. Although putative cell death specific Insulin-like growth factor binding protein-3 (IGFBP-3R) receptor(s) has recently been identified by which IGFBP-3 may induce its anti-tumor effects, IGFBP-3 has also been known to activate various downstream intracellular signaling molecules via a different mechanistic pathway. Stat-1 has been known to be one of the candidate molecules activated by IGFBP-3. IGFBP-3 can also inhibit Akt/IGF-1 survival pathway in MCF-7 breast cancer cells which ultimately leads to the induction of apoptosis in these cells. All these studies clearly demonstrate that IGFBP-3 regulates cell proliferation and promotes its pro-apoptotic effects in cancer cells in two different pathways: 1) sequester IGF-I to bind to IGF-I receptor to inhibit cell proliferation and induce apoptosis, 2) independent of IGF-I pathway, IGFBP-3 binds to some putative receptor and activate various downstream pro-apoptotic molecules involved in cell death.

Keywords

Apoptosis, IGFBP-3, Stat-1, IGF-I, TGF-β

1. IGFBP-3 Expression and Function

Insulin-like growth factor binding protein-3 (IGFBP-3) is one of the six known IGF binding proteins present in human serum and is comprised of 264-amino acid mature protein, with a 27-amino acid signal peptide [1] . IGFBP-3 is expressed in a wide variety of tissues. Epidemiological studies have clearly suggested that there is an inverse relationship between IGFBP-3 levels and occurrence of cancers [2] . Increased expression levels of serum IGFBP-3 result in decreased prevalence of prostate [3] [4] and colorectal [5] [6] cancers. It has also been shown that IGFBP-3 over expression results in decreased tumor formation in xenografts of non-small lung cancer cells [7] and M12 human prostate cancer cells [8] . Patient samples with hepatocellular and non-small cell lung carcinoma have been shown to have decreased expression of IGFBP-3 [9] [10] . Besides, it has also been reported that there is an increased level of IGFBP-3 in senescence [11] . In addition, IGFBP-3 expression level was decreased in cells immortalized with the human papillomavirus type 16 oncoprotein E7 due to proteasomal degradation [12] . Although IGFBP-3 is a secretory protein, but active protein could also be found in nucleus and cytoplasm [13] . Besides its full length form, IGFBP-3 could also be found in an N-terminal truncated form [14] [15] .

IGFBP-3 has been known to play an important role in cell proliferation by inducing its anti-proliferative and pro-apoptotic effects in breast and prostate cancer cells [16] -[18] . It has also been shown that IGFBP-3 not only triggers growth inhibitory effects by inducing apoptosis, but also can function in G1 cell cycle arrest in human breast, kidney and lung cancer cells [19] [20] . IGFBP-3 may also play an important role in mediating inhibitory effects of transforming growth factor (TGF)-β (Figure 1), retinoic acid, tumor necrosis factor (TNF)-α and p53 [16] [21] -[26] , but modulation in IGFBP-3 synthesis or action could regulate these anti-proliferative effects.

2. IGF-Dependent and Independent Effect of IGFBP-3

IGF dependent studies revealed that Insulin-like growth factor binding protein (IGFBP)-3 could induce apoptosis by binding to IGF-I and form a binary complex with IGF-I and prevent it to activate (IGF-IR) IGF-1 receptor (Figure 2) to stimulate cell proliferation and survival [27] [28] . In addition, Insulin-like growth factor binding protein (IGFBP)-3 has been shown to potently inhibit cell proliferation and induce apoptosis in an insulin-like growth factor (IGF)-independent manner [13] [18] [29] . IGFBP-3 in the media may exert its pro-apoptotic effects by binding to some cell surface receptors resulting in the activation of various signal transduction pathways.

Figure 1. Key candidate molecules activated by IGFBP-3. IGFBP-3 can activate various downstream signaling molecules either by binding to its putative IGFBP-3R (receptor) to monitor its signal and induce apoptosis or bind to TGF-β receptor resulting in Smad activation which leads to apoptosis. IGFBP- 3 can also activate Stat-1 or bind to RXR-α to induce its anti-proliferative and pro-apoptotic effects.

Figure 2. IGF dependent and independent effects of IGFBP-3. IGF-1 can bind to IGF-I receptor and stimulate cell proliferation. IGFBP-3 blocks IGF-I to bind to its receptor resulting in the induction of apoptosis. IGFBP-3 can also induce apoptosis on its own by IGF-I independent mechanism.

Figure 3. IGFBP-3 entry into the cell by different pathways. IGFBP-3 in the media seemingly binds with plasma membrane IGFBP-3 receptor to activate signal transduction pathway or enters into the cell by endocytosis to induce apoptosis. IGFBP-3 may either directly activate signal transduction pathway by binding to some receptor to induce apoptosis or in the form of vesicular IGFBP-3 which enters through endoplasmic reticulum membrane into the cytosol and possibly gets translocated into the nucleus.

Alternatively, IGFBP-3 may possibly enter into the cell by endocytosis (Figure 3). It has also been reported in some other studies that IGFBP-3 binds to RXRα (Figure 1) and induce its pro-apoptotic effects in PC-3 human prostate cancer cells [30] . Surprisingly, recent studies have shown that IGFBP-3 fail to gain entry or be internalized upon binding to IGF-1 in the extracellular media to induce its pro-apoptotic effects in non-transformed mammary epithelial cells [31] .

3. Pathways Involved in IGFBP-3 Signaling

IGFBP-3 action results in the activation of various signal transduction pathways [32] and Stat-1 (signal transducer and activator of transcription 1) has been known to have a functional role in IGFBP-3-induced apoptosis (Figure 1) in rat chondroprogenitor cells [33] , although our previous studies [34] showed a protective role of Stat-1 on IGFBP-3 induced apoptosis in PC-3 human prostate cancer cells, implying the fact that role of Stat-1 may be cell type dependent.

Some other downstream signaling molecules of IGFBP-3 have also been reported in various other studies [16] [35] [36] . It has been shown from these studies that IGFBP-3 can bind to transforming growth factor-β (TGF-β) cell surface receptors and one of the studies have shown direct interaction of IGFBP-3 with TGF-β-receptor typeV (TGF-β-RV) in mink lung epithelial cells [37] .

IGFBP-3 has also been known to bind and activate intracellular signaling by forming a hetero-meric complex with other TGF-β receptors (TGF-β RII and TGF-β RI) in T47D breast cancer cells [35] [36] . Besides, addition of IGFBP-3 resulted in the activation of Smad 2 phosphorylation and cell growth inhibition in these cells. It has also been shown that IGFBP-3 mediates its pro-apoptotic effects via TGF-β in PC-3 human prostate cancer cells [16] . Results from our previous studies indicated the inhibition of TGF-β signaling in presence of IGFBP-3 in PC-3 human prostate cancer cells [34] , although we did not study the Smad activation in these cells.

It has also been reported that IGFBP-3 down-regulates Akt activity in human epidermal growth factor receptor-2 (HER-2) over expressed MCF-7 breast cancer cells [38] , in this regard recent studies have shown that IGFBP-3 induces apoptosis in MCF-7 breast cancer cells by inhibiting IGF-I/Akt survival pathway [39] . Previous studies also indicated that IGFBP-3 can bind to a new cell death receptor (IGFBP-3R), a single-span membrane protein which specifically binds to IGFBP-3 but doesn’t bind to other IGFBP’s. In vivo studies using prostate and breast cancer xenografts in athymic nude mice, showed anti-tumor effects of IGFBP-3R [40] . It was shown from the in vitro studies that IGFBP-3R triggers IGFBP-3 induced apoptosis in various cancer cells via a caspase-8 dependent pathway. IGFBP-3R directly interacts and activates caspase-8 in inducing apoptosis and knockdown of caspase-8 expression or activity can lead to inhibition of IGFBP-3/IGFBP-3R induced apoptosis. All these studies clearly indicate that IGFBP-3 induces its anti-proliferative and pro-apoptotic effects either by sequestering IGF-1 to prevent it to bind to Insulin-like growth factor-I receptor (IGF-IR) in an IGF dependent manner or by activating several candidate molecules via signal transduction pathway independent of IGF binding. Although insulin-like growth factor binding protein-3 receptor (IGFBP-3R) has been known to be directly involved in IGFBP-3 action and may prove to be an important target molecule for the treatment of cancer, further studies are still needed to clarify the role of this receptor or other IGFBP-3 cell surface binding protein(s) in IGFBP-3 mediated cell signaling events.

4. Conclusion

IGFBP-3 is known to activate various downstream signaling molecules. Some of these signaling events could be initiated after binding to its receptor independent of IGF-I binding, to induce anti-proliferative and pro-apoptotic effects in a certain type of cancer cells. On the other hand, IGFBP-3 can also bind to IGF-1 to modulate its ability to bind to IGF-1 receptor to inhibit cell proliferation and cell survival, resulting in cell death.

Funding

This work was supported by an intramural grant from NIDDK, NIH.

NOTES

^*Corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Wood, W.I., Cachianes, G., Henzel, W.J., Winslow, G.A., Spencer, S.A., Hellmiss, R., Martin, J.L. and Baxter, R.C. (1988) Cloning and Expression of the Growth Hormone-Dependent Insulin-Like Growth Factor-Binding Protein. Molecular Endocrinology, 2, 1176-1185. http://dx.doi.org/10.1210/mend-2-12-1176
[2]	Mehta, H.H., Gao, Q., Galet, C., Paharkova, V., Wan, J., Said, J., Sohn, J.J., Lawson, G., Cohen, P., Cobb, L.J. and Lee, K.W. (2011) IGFBP-3 Is a Metastasis Suppression Gene in Prostate Cancer. Cancer Research, 71, 5154-5163. http://dx.doi.org/10.1158/0008-5472.CAN-10-4513
[3]	Chan, J.M., Stampfer, M.J., Giovannucci, E., Gann, P.H., Ma, J., Wilkinson, P., Hennekens, C.H. and Pollak, M. (1998) Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study. Science, 279, 563-566. http://dx.doi.org/10.1126/science.279.5350.563
[4]	Chan, J.M., Stampfer, M.J., Ma, J., Gann, P., Gaziano, J.M., Pollak, M. and Giovannucci, E. (2002) Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer. Journal of the National Cancer Institute, 94, 1099-1106. http://dx.doi.org/10.1093/jnci/94.14.1099
[5]	Ma, J., Pollak, M.N., Giovannucci, E., Chan, J.M., Tao, Y., Hennekens, C.H. and Stampfer, M.J. (1999) Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. Journal of the National Cancer Institute, 91, 620-625. http://dx.doi.org/10.1093/jnci/91.7.620
[6]	Giovannucci, E., Pollak, M.N., Platz, E.A., Willett, W.C., Stampfer, M.J., Majeed, N., Colditz, G.A., Speizer, F.E. and Hankinson, S.E. (2000) A Prospective Study of Plasma Insulin-Like Growth Factor-1 and Binding Protein-3 and Risk of Colorectal Neoplasia in Women. Cancer Epidemiological Biomarkers Preview, 9, 345-349.
[7]	Hochscheid, R., Jaques, G. and Wegmann, B. (2000) Transfection of Human Insulin-Like Growth Factor-Binding Protein 3 Gene Inhibits Cell Growth and Tumorigenicity: A Cell Culture Model for Lung Cancer. Journal of Endocrinology, 166, 553-563. http://dx.doi.org/10.1677/joe.0.1660553
[8]	Devi, G.R., Sprenger, C.C., Plymate, S.R. and Rosenfeld, R.G. (2002) Insulin-Like Growth Factor Binding Protein-3 Induces Early Apoptosis in Malignant Prostate Cancer Cells and Inhibits Tumor Formation in Vivo. Prostate, 51, 141-152. http://dx.doi.org/10.1002/pros.10068
[9]	Hanafusa, T., Yumoto, Y., Nouso, K., Nakatsukasa, H., Onishi, T., Fujikawa, T., Taniyama, M., Nakamura, S., Uemura, M., Takuma, Y., Yumoto, E., Higashi, T. and Tsuji, T. (2002) Reduced Expression of Insulin-Like Growth Factor Binding Protein-3 and Its Promoter Hypermethylation in Human Hepatocellular Carcinoma. Cancer Letters, 176, 149-158. http://dx.doi.org/10.1016/S0304-3835(01)00736-4
[10]	Chang, Y.S., Kong, G., Sun, S., Liu, D., El-Naggar, A.K., Khuri, F.R., Hong, W.K. and Lee, H.Y. (2002) Clinical Significance of Insulin-Like Growth Factor-Binding Protein-3 Expression in Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research, 8, 3796-3802.
[11]	Lu, X.F., Jiang, X.G., Lu, Y.B., Bai, J.H. and Mao, Z.B. (2005) Characterization of a Novel Positive Transcription Regulatory Element That Differentially Regulates the Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Gene in Senescent Cells. Journal of Biological Chemistry, 280, 22606-22615. http://dx.doi.org/10.1074/jbc.M412073200
[12]	Mannhardt, B., Weinzimer, S.A., Wagner, M., Fiedler, M., Cohen, P., Jansen-Durr, P. and Zwerschke, W. (2000) Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3. Molecular and Cellular Biology, 20, 6483-6495. http://dx.doi.org/10.1128/MCB.20.17.6483-6495.2000
[13]	Bhattacharyya, N., Pechhold, K., Shahjee, H., Zappala, G., Elbi, C., Raaka, B., Wiench, M., Hong, J. and Rechler, M.M. (2006) Nonsecreted Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Can Induce Apoptosis in Human Prostate Cancer Cells by IGF-Independent Mechanisms without Being Concentrated in the Nucleus. Journal of Biological Chemistry, 281, 24588-24601. http://dx.doi.org/10.1074/jbc.M509463200
[14]	Lalou, C., Lassarre, C. and Binoux, M. (1996) A Proteolytic Fragment of Insulin-Like Growth Factor (IGF) Binding Protein-3 That Fails to Bind IGFs Inhibits the Mitogenic Effects of IGF-I and Insulin. Endocrinology, 137, 3206-3212.
[15]	Shahjee, H., Bhattacharyya, N., Zappala, G., Wiench, M., Prakash, S. and Rechler, M.M. (2008) An N-Terminal Fragment of Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) Induces Apoptosis in Human Prostate Cancer Cells in an IGF-Independent Manner. Growth Hormone & IGF Research, 18, 188-197. http://dx.doi.org/10.1016/j.ghir.2007.08.006
[16]	Rajah, R., Valentinis, B. and Cohen, P. (1997) Insulin-Like Growth Factor IGF Binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-In- dependent Mechanism. Journal of Biological Chemistry, 272, 12181-12188. http://dx.doi.org/10.1074/jbc.272.18.12181
[17]	Butt, A.J., Firth, S.M., King, M.A. and Baxter, R.C. (2000) Insulin-Like Growth Factor-Binding Protein-3 Modulates Expression of Bax and Bcl-2 and Potentiates p53-Independent Radiation-Induced Apoptosis in Human Breast Cancer Cells. Journal of Biological Chemistry, 275, 39174-39181. http://dx.doi.org/10.1074/jbc.M908888199
[18]	Hong, J., Zhang, G., Dong, F. and Rechler, M.M. (2002) Insulin-Like Growth Factor (IGF)-Binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells. Journal of Biological Chemistry, 277, 10489-10497. http://dx.doi.org/10.1074/jbc.M109604200
[19]	Kim, H.S., Lee, W.J., Lee, S.W., Chae, H.W., Kim, D.H. and Oh, Y. (2010) Insulin-Like Growth Factor Binding Protein-3 Induces G1 Cell Cycle Arrest with Inhibition of Cyclin-Dependent Kinase 2 and 4 in MCF-7 Human Breast Cancer Cells. Hormone and Metabolic Research, 42, 165-172.
[20]	Wu, C., Liu, X.B., Wang, Y.Y., Tian, H.N., Xie, Y.Y., Li, Q.J., Zhang, X.K. and Liu, F.M. (2013) Insulin-Like Factor Binding Protein-3 Promotes the G1 Cell Cycle Arrest in Several Cancer Cell Lines. Gene, 512, 127-133. http://dx.doi.org/10.1016/j.gene.2012.09.080
[21]	Gucev, Z.S., Oh, Y., Kelley, K.M. and Rosenfeld, R.G. (1996) Insulin-Like Growth Factor Binding Protein-3 Mediates Retinoic Acid- and Transforming Growth Factor Beta2-Induced Growth Inhibition in Human Breast Cancer Cells. Cancer Research, 56, 1545-1550.
[22]	Rajah, R., Lee, K.W. and Cohen, P. (2002) Insulin-Like Growth Factor Binding Protein-3 Mediates Tumor Necrosis Factor-Alpha-Induced Apoptosis: Role of Bcl-2 Phosphorylation. Cell Growth & Differentiation, 13, 163-171.
[23]	Vasylyeva, T.L., Chen, X. and Ferry Jr., R.J. (2005) Insulin-Like Growth Factor Binding Protein-3 Mediates Cytokine-Induced Mesangial Cell Apoptosis. Growth Hormone & IGF Research, 15, 207-214. http://dx.doi.org/10.1016/j.ghir.2005.02.008
[24]	Ryan, K.M. and Vousden, K.H. (1998) Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest. Molecular and Cellular Biology, 18, 3692-3698.
[25]	Grimberg, A., Liu, B., Bannerman, P., El-Deiry, W.S. and Cohen, P. (2002) IGFBP-3 Mediates p53-Induced Apoptosis during Serum Starvation. International Journal of Oncology, 21, 327-335.
[26]	Harms, K.L. and Chen, X. (2005) The C Terminus of p53 Family Proteins Is a Cell Fate Determinant. Molecular and Cellular Biology, 25, 2014-2030. http://dx.doi.org/10.1128/MCB.25.5.2014-2030.2005
[27]	Rechler, M.M. and Clemmons, D.R. (1998) Regulatory Actions of Insulin-Like Growth Factor-Binding Proteins. Trends in Endocrinology and Metabolism, 9, 176-183. http://dx.doi.org/10.1016/S1043-2760(98)00047-2
[28]	Firth, S.M. and Baxter, R.C. (2002) Cellular Actions of the Insulin-Like Growth Factor Binding Proteins. Endocrine Reviews, 23, 824-854. http://dx.doi.org/10.1210/er.2001-0033
[29]	Han, J., Jogie-Brahmin, S., Harada, A. and Oh, Y. (2011) Insulin-Like Growth Factor-Binding Protein-3 Suppresses tumor Growth via Activation of Caspase-Dependent Apoptosis and Cross-Talk with NF-κB Signaling. Cancer Letters, 307, 200-210. http://dx.doi.org/10.1016/j.canlet.2011.04.004
[30]	Zappala, G., Elbi, C., Edwards, J., Gorenstein, J., Rechler, M.M. and Bhattacharyya, N. (2008) Induction of Apoptosis in Human Prostate Cancer Cells by Insulin-Like Growth Factor Binding Protein-3 Does Not Require Binding to Retinoid X Receptor-α. Endocrinology, 149, 1802-1812. http://dx.doi.org/10.1210/en.2007-1315
[31]	Leibowitz, B.J., Agostini-Dreyer, A., Jetzt, A.E., Krumm, C.S. and Cohick, W.S. (2013) IGF Binding Protein-3 Mediates Stress-Induced Apoptosis in Non-Transformed Mammary Epithelial Cells. Journal of Cellular Physiology, 228, 734-742. http://dx.doi.org/10.1002/jcp.24220
[32]	Ricort, J.M. (2004) Insulin-Like Growth Factor Binding Protein (IGFBP) Signalling. Growth Hormone & IGF Research, 14, 277-286. http://dx.doi.org/10.1016/j.ghir.2004.02.002
[33]	Spagnoli, A., Torello, M., Nagalla, S.R., Horton, W.A., Pattee, P., Chiarelli, F., Roberts Jr., C.T. and Rosenfeld, R.G. (2002) Identification of STAT-1 as a Molecular Target of IGFBP-3 in the Process of Chondrogenesis. Journal of Biological Chemistry, 277, 18860-18867. http://dx.doi.org/10.1074/jbc.M200218200
[34]	Shahjee, H.M., Kefas, B., Bhattacharyya, N. and Radwan, M.K. (2013) Signal Transduction Pathways Mediated by Secreted and Non-Secreted Forms of Intact Insulin-Like Growth Factor Binding Protein-3 and Its 1-97 N-Terminal Fragment in PC-3 Human Prostate Cancer Cells. Journal of Cancer Therapy, 4, 1290-1297. http://dx.doi.org/10.4236/jct.2013.48152
[35]	Fanayan, S., Firth, S.M., Butt, A.J. and Baxter, R.C. (2000) Growth Inhibition by Insulin-Like Growth Factor-Binding Protein-3 in T47D Breast Cancer Cells Requires Transforming Growth Factor-β (TGF-β) and the Type II TGF-β Receptor. Journal of Biological Chemistry, 275, 39146-39151. http://dx.doi.org/10.1074/jbc.M006964200
[36]	Fanayan, S., Firth, S.M. and Baxter, R.C. (2002) Signalling through the Smad Pathway by Insulin-Like Growth Factor-Binding Protein-3 in Breast Cancer Cells. Relationship to Transforming Growth Factor-β1 Signaling. Journal of Biological Chemistry, 277, 7255-7261. http://dx.doi.org/10.1074/jbc.M108038200
[37]	Leal, S.M., Huang, S.S. and Huang, J.S. (1999) Interactions of High Affinity Insulin-Like Growth Factor-Binding Proteins with the Type V Transforming Growth Factor-β Receptor in Mink Lung Epithelial Cells. Journal of Biological Chemistry, 274, 6711-6717. http://dx.doi.org/10.1074/jbc.274.10.6711
[38]	Jerome, L., Alami, N., Belanger, S., Page, V., Yu, Q., Paterson, J., Shiry, L., Pegram, M. and Leyland-Jones, B. (2006) Recombinant Human Insulin-Like Growth Factor Binding Protein-3 Inhibits Growth of Human Epidermal Growth Factor Receptor-2 Overexpressing Breast Tumors and Potentiates Herceptin Activity in Vivo. Cancer Research, 66, 7245-7252. http://dx.doi.org/10.1158/0008-5472.CAN-05-3555
[39]	Brosseau, C., Pirianov, G. and Colston, K.W. (2013) Role of Insulin-Like Growth Factor Binding Protein-3 in 1,25-Dihydroxyvitamin-D3-Induced Breast Cancer Cell Apoptosis. International Journal of Cell Biology, 2013, Article ID: 960378. http://dx.doi.org/10.1155/2013/960378
[40]	Ingermann, A.R., Yang, Y.F., Han, J., Mikami, A., Garza, A.E., Mohanraj, L., Fan, L., Idowu, M., Ware, J.L., Kim, H.S., Lee, D.Y. and Oh, Y. (2010) Identification of a Novel Cell Death Receptor Mediating IGFBP-3-Induced Anti-Tumor Effects in Breast and Prostate Cancer. Journal of Biological Chemistry, 285, 30233-30246. http://dx.doi.org/10.1074/jbc.M110.122226